Sheri McCoy is former Chief Executive Officer and Director of Avon Products, Inc. Prior to Avon, Ms. McCoy had a distinguished 30-year career at Johnson & Johnson serving as Vice Chairman of the Executive Committee, responsible for the Pharmaceutical and Consumer business segments that represented more than 60 percent of the company’s revenues. Ms. McCoy joined Johnson & Johnson as a scientist in research and development and subsequently managed businesses in every major product sector, including consumer, prescription medicines, and medical devices, where she held roles including Worldwide Chairman, Pharmaceuticals Group and Worldwide Chairman, Surgical Care Group. Ms. McCoy has experience in mergers and acquisitions and management of complex global structures.
In addition to serving as Chairman at Certara, Sheri serves on the boards of AstraZeneca PLC, a global, science-led biopharmaceutical business; Stryker Corporation, a Fortune 500 medical technologies firm; Kimberly-Clark, a multinational personal care corporation; and Novocure, a novel oncology company. She is also an industrial adviser for EQT, in connection with which she chairs Certara and Aldevron, leading supplier of DNA plasmids, and serves as a director at Galderma, a skin health business.
Ms. McCoy holds a Bachelor of Science degree in textile chemistry from the University of Massachusetts, Dartmouth, a Master’s degree in chemical engineering from Princeton University, and an MBA from Rutgers University. She holds four US patents, and she has been on Fortune magazine’s “50 Most Powerful Women in Business” list.
Jim Cashman is an veteran of the software industry for over 45 years, and serves as an advisor to numerous high tech companies. He most recently served for 20 years in the CEO and Executive Chairman roles of ANSYS, Inc. which grew from $50 million to over $1 billion in revenues over his tenure. During that span, ANSYS was one of the top 5 public technology companies in terms of total shareholder returns, while joining the S&P500 and NASDAQ-100. He has evangelized Simulation Driven Product Development which enables organizations to develop virtual prototypes, resulting in reduced testing, faster time-to-market, and better quality products. As such, he has been featured in many publications, as well as on CNBC, CNN, FBN, Bloomberg and other on-air networks.
Cynthia Collins served as Chief Executive Officer of Editas Medicine, Inc. (Nasdaq:EDIT) from March 2019 to February 2021 and served as a member of the board of directors of Editas Medicine from December 2018 to February 2021. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc. and Chief Executive Officer/General Manager of General Electric’s Healthcare Cell Therapy and Lab Businesses and GE’s Clarient Diagnostics. Prior to GE, Ms. Collins served as CEO of GenVec (NASDAQ:GNVC), a vaccine and gene therapy company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter with responsibility for its Hematology, Flow Cytometry, and Hemostasis businesses.
Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA from The University of Chicago Booth School of Business. She is currently a member of the board of DermTech, Inc.
Dr. Feehery joined Certara in June, 2019 as CEO. Dr. Feehery joins Certara from DuPont, where he has served since 2013 as president of DuPont Industrial Biosciences, a $2.2 billion global biotechnology business which experienced significant growth and profitability under his leadership. In that role, he had full P&L responsibility for 3,000 people, including 500 R&D staff, 20 manufacturing plants, and worldwide marketing and sales across multiple markets. He joined DuPont in 2002 and has prior experience in venture capital and as a consultant for the Boston Consulting Group.
Dr. Feehery also serves as a board member for West Pharmaceutical Services (NYSE: WST), a manufacturer of packing components and delivery systems for pharmaceutical, biotech and medical device companies.
Dr. Feehery holds both a PhD in chemical engineering and an MBA from MIT. He was a Churchill Scholar at Cambridge University, and received his BSE in chemical engineering from the University of Pennsylvania. His doctorate, awarded while he was the recipient of a National Science Foundation Fellowship, involved developing software and mathematical methods for modeling complex systems.
Carol Gallagher, Pharm.D. is an experienced board director having served as a director in both public and private companies since 2011. From 1989 to 2011, Dr. Gallagher enjoyed a successful and varied career in both large and small biopharmaceutical companies. She started her career in sales and marketing at Eli Lilly and held various positions of increasing responsibility in commercial, drug development and business development at companies such as Amgen, Agouron Pharmaceuticals, Pfizer, and IDEC Pharmaceuticals.
Starting in 2008, Dr. Gallagher was President and CEO of Calistoga Pharmaceuticals where she led the development of first-in-class cancer therapeutic, ZYDELIG. Calistoga Pharmaceuticals was acquired by Gilead in 2011, and ZYDELIG was approved in the US and EU in 2014. She currently serves as a Venture Partner at New Enterprise Associates whom she represents as a director on four private company boards. In addition to Certara, she is a director at Turning Point Therapeutics (TPTX), Atara Biotherapeutics (ATRA) and Frazier Life Sciences Acquisition (FLACU). She has experience chairing Audit, Compensation, and Nominating and Governance committees. Dr. Gallagher attended Vanderbilt University and received Bachelor of Science and Doctor of Pharmacy degrees from the University of Kentucky College of Pharmacy.
Nancy Killefer served as a Senior Partner at McKinsey & Company, an international management consulting firm, from 1992 until her retirement in August 2013. She joined McKinsey in 1979 and held a number of leadership roles, including serving as a member of the firm’s governing board. Ms. Killefer also served as Assistant Secretary for Management, Chief Financial Officer, and Chief Operating Officer of the U.S. Department of the Treasury from 1997 to 2000 and as a member of the IRS Oversight Board from 2000 to 2005, including as Chair of the IRS Oversight Board from 2002 to 2004.
Ms. Killefer holds a B.A. in economics from Vassar College and an M.S. in management from the Massachusetts Institute of Technology.
Ms. Killefer also serves on the boards of directors of Facebook, Inc. since March 2020, Cardinal Health, Inc., a healthcare services company, since September 2015 and Natura & Company, a global personal care cosmetics group, since January 2020.
Eric Liu is a Partner and Global Co-Head of Healthcare at EQT. EQT is an alternative asset management firm headquartered in Sweden, with €41 billion in assets under management. He joined in 2014 to establish and build out the firm’s large-cap buyout operations in the U.S. The firm is currently investing EQT VIII, an €11 billion private equity fund raised in 2018. Eric led the firm’s investments and serves on the Board of Directors of Aldevron, Certara, Waystar, and Press Ganey (former). Prior to joining EQT, Eric spent ten years at Warburg Pincus where he was responsible for private equity investments in the healthcare sector, including Bausch & Lomb, Tornier, ev3, and DexCom. Earlier in his career, he worked in private equity at The Blackstone Group and in early-stage venture capital at Draper Fisher Jurvetson.
Eric has a B.A. in Applied Mathematics, phi beta kappa, from Harvard University and an MBA from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar.
Mr. McLean is the Senior Partner, Healthcare Group at Arsenal Capital Partners, a New York City-based private equity firm. Previously, Mr. McLean was a founding Partner of Merrill Lynch Capital Partners, Inc. McLean serves on a number of corporate boards including WCG Clinical, CellCarta, BioIVT and Value Demonstration. He is the Chairman and a founder of the International Biomedical Research Alliance. McLean holds a BS in Economics, summa cum laude and an MBA with Distinction, both earned from the Wharton School of the University of Pennsylvania.
Mr. Slaine is Chairman of the Board and investor in Cast & Crew and is a Board Member and investor in Reorg Inc and Certara LLC. He is also Executive Chairman of MLM2 and a principal investor in Varo Bank.
Most recently, Mr. Slaine was a Board member and investor in RS Energy, which was acquired by Genstar in February 2020 and Efront Holdings, which was acquired by BlackRock in May 2019. He was also Chairman and co-investor in FT Media Holdings, which was acquired by Gannett in 2018. Furthermore, Mr. Slaine was a Board Member and investor in IPAN GMBH, which was acquired by Castik Capital in June 2018 and Bureau Van Dijk, which was acquired by Moody’s Corporation in August 2017. From 2010 to 2015, Mr. Slaine was Executive Chairman of Interactive Data Corporation (IDC). IDC was acquired in December 2015 by The Intercontinental Exchange (ICE – NYSE).
Mr. Slaine was previously a principal owner and Board Member of iParadigms LLC. He was also Chairman, President and CEO as well as a principal investor in MLM Information Services, a leading SAS provider of corporate tax compliance software and services, which he co- founded in 2006 and sold in 2011 to Corporation Services Company (CSC). Prior to this role, Mr. Slaine was chairman and CEO of Information Holdings, a business he co-founded in 1997 and which was listed on the New York Stock Exchange from 1998- 2004. IHI was acquired by Thomson in 2004.
From 1994 to 1996, Mr. Slaine was President and CEO of Thomson Financial (now Thomson Reuters) and held various executive positions at Thomson from 1991 to 1993. From 1987 to 1991, he was chairman and CEO of Securities Data Co until its acquisition by the Thomson Corporation. From 1982 to 1986, Mr. Slaine was President and CEO, founder and a principal owner of Dealers Digest Inc., a financial information provider until its acquisition by Extel PLC.
Mr. Slaine holds an A.B., magna cum laude, from Amherst College and an MBA from Harvard University.
Mr. Matthew Walsh currently serves as Executive Vice President and Chief Financial Officer of Organon & Co., a global pharmaceutical business within Merck that is planned to be spun off in 2021. Prior to Organon, he served as Executive Vice President and Chief Financial Officer of Allergan, a publicly traded, global biopharmaceutical company, from 2018 until the sale of the company to Abbvie in 2020. From 2008 to 2018, Mr. Walsh served as Chief Financial Officer of Catalent, a global provider of delivery technologies, development, and manufacturing solutions to the life sciences industry. During his tenure, Catalent successfully completed the largest healthcare IPO of 2014. Before Catalent, from 2006 to 2008, he was President, Chief Financial Officer and Acting Chief Executive Officer at Escala Group, Inc.
Mr. Walsh previously held a variety of finance leadership roles at industrial manufacturer GenTek, Inc., including Chief Financial Officer, Treasurer, and Group Controller. He served on the board of directors of Multicolor Corporation from 2015 to 2017.
Mr. Walsh earned his Bachelor of Science degree in chemical engineering from Cornell University, and an M.B.A. from Cornell University, SC Johnson School of Management. Mr. Walsh is a CFA® charterholder.
Ethan Waxman is a Director at EQT, an alternative asset management firm headquartered in Sweden with €41 billion in assets under management. At EQT, Ethan has been involved in the firm’s investments in Certara, Waystar, Press Ganey (former), and Clinical Innovations (former). Prior to joining EQT, Ethan worked at Warburg Pincus.
Ethan has a B.A., phi beta kappa, from Harvard University.